CEO Granted Substantial Performance Share Units Tied to Key FDA Milestones

summarizeSummary

DBV Technologies' CEO, Daniel Tassé, was granted 1.74 million performance share units (PSUs) with vesting contingent on FDA acceptance of Biologics License Applications for Viaskin Peanut in two age groups.

check_boxKey Events

• CEO Performance Share Grant

  Daniel Tassé, CEO, was granted 1,740,000 Performance Share Units (PSUs) on May 5, 2026.

• FDA Milestone Vesting

  Vesting of PSUs is contingent on FDA acceptance for review of Biologics License Applications (BLAs) for Viaskin Peanut in patients aged 4-7 years and 1-3 years. Each condition accounts for 50% of the PSUs.

• Long-Term Incentive

  The PSUs are subject to continued employment through July 1, 2028, with vested shares delivered in installments through January 2030, aligning CEO compensation with long-term company performance and regulatory success.

• Significant Potential Value

  If fully vested, these PSUs represent a substantial potential compensation package for the CEO, underscoring the importance of the regulatory milestones for the company's flagship product.

auto_awesomeAnalysis

This significant performance-based compensation package for the CEO directly aligns his incentives with the successful regulatory progression of Viaskin Peanut, the company's lead product. The vesting of these PSUs is entirely dependent on achieving critical FDA acceptance milestones for both the 4-7 and 1-3 year age groups by July 2028. This structure signals strong management confidence in the product's potential and a clear focus on advancing it through the regulatory process, which is crucial for the company's future value creation following recent positive Phase 3 results and financing.